

Nicoletta Cicarelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6024175/publications.pdf>

Version: 2024-02-01

46
papers

1,145
citations

394421

19
h-index

395702

33
g-index

47
all docs

47
docs citations

47
times ranked

1662
citing authors

#	ARTICLE	IF	CITATIONS
1	Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. <i>Neurology</i> , 2011, 76, 1403-1409.	1.1	217
2	Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. <i>HIV Medicine</i> , 2013, 14, 136-144.	2.2	77
3	Semantic memory in object use. <i>Neuropsychologia</i> , 2009, 47, 2634-2641.	1.6	64
4	Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw557.	3.0	62
5	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. <i>Neuropsychologia</i> , 2012, 50, 1980-1989.	1.6	53
6	Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia. <i>Antiviral Therapy</i> , 2013, 18, 153-160.	1.0	52
7	The deficit for the word-class "verb" in corticobasal degeneration: Linguistic expression of the movement disorder?. <i>Neuropsychologia</i> , 2007, 45, 2570-2579.	1.6	46
8	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment) Tj ETQq0 0 0 rgBT /Overlock 10 Tr 50 452 To	3.0	45
9	Efficacy and safety of treatment simplification to atazanavir/ritonavir+lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1843-1849.	3.0	38
10	Comparison of cognitive performance in HIV or HCV mono-infected and HIV+HCV co-infected patients. <i>Infection</i> , 2013, 41, 1103-1109.	4.7	35
11	Naming of Grammatical Classes in Frontotemporal Dementias: Linguistic and Non Linguistic Factors Contribute to Noun-Verb Dissociation. <i>Behavioural Neurology</i> , 2007, 18, 197-206.	2.1	34
12	Antiretroviral Neuropenetration Scores Better Correlate with Cognitive Performance of HIV-Infected Patients after Accounting for drug Susceptibility. <i>Antiviral Therapy</i> , 2015, 20, 441-447.	1.0	34
13	Cognitive reserve and neuropsychological functioning in older HIV-infected people. <i>Journal of NeuroVirology</i> , 2016, 22, 575-583.	2.1	33
14	Effect of Aging and Human Immunodeficiency Virus Infection on Cognitive Abilities. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 2048-2055.	2.6	30
15	Unilateral spatial neglect in degenerative brain pathology.. <i>Neuropsychology</i> , 2011, 25, 554-566.	1.3	29
16	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1955-1964.	3.0	29
17	<i>SLC22A2</i> variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1035-1043.	3.0	24
18	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 34-45.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: Table 1. Journal of Antimicrobial Chemotherapy, 2016, 71, 2359-2361.	3.0	22
20	The role of cognitive reserve in cognitive aging: what we can learn from Parkinson's disease. Aging Clinical and Experimental Research, 2018, 30, 877-880.	2.9	21
21	Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). Clinical Neuropsychologist, 2016, 30, 1457-1468.	2.3	19
22	Considerations on nosology for HIV-associated neurocognitive disorders: it is time to update?. Infection, 2020, 48, 37-42.	4.7	17
23	Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. Journal of Infection, 2012, 65, 439-446.	3.3	16
24	Primary progressive aphasia: Linguistic patterns and clinical variants. Brain and Language, 2014, 135, 57-65.	1.6	13
25	Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance. BMC Psychology, 2013, 1, 3.	2.1	11
26	Posterior AD-Type Pathology: Cognitive Subtypes Emerging from a Cluster Analysis. Behavioural Neurology, 2014, 2014, 1-8.	2.1	11
27	Baseline CD4 ⁺ T-cell Count and Cardiovascular Risk Factors Predict the Evolution of Cognitive Performance During 2-Year follow-up in HIV-Infected Patients. Antiviral Therapy, 2015, 20, 433-440.	1.0	11
28	Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the 'cortical hypothesis' of NeuroAIDS. Applied Neuropsychology Adult, 2017, 24, 410-419.	1.2	11
29	Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA. Journal of Clinical Virology, 2017, 91, 18-24.	3.1	8
30	Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients. Journal of NeuroVirology, 2019, 25, 866-873.	2.1	8
31	Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre. Journal of the International AIDS Society, 2014, 17, 19817.	3.0	7
32	Cognitive reserve: a multidimensional protective factor in Parkinson's disease related cognitive impairment. Aging, Neuropsychology, and Cognition, 2022, 29, 687-702.	1.3	7
33	Liver fibrosis is associated with cognitive impairment in HIV-positive patients. Journal of the International AIDS Society, 2014, 17, 19722.	3.0	5
34	Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study. International Journal of Medical Informatics, 2021, 156, 104616.	3.3	5
35	Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA. Journal of the International AIDS Society, 2014, 17, 19791.	3.0	4
36	Emotional valence may influence memory performance for visual artworks in Parkinson's disease. Neurological Sciences, 2019, 40, 2175-2178.	1.9	4

#	ARTICLE	IF	CITATIONS
37	Liver fibrosis is associated with cognitive impairment in people living with HIV. <i>Infection</i> , 2019, 47, 589-593.	4.7	4
38	Degenerative and Vascular Fluent Aphasia: Looking for Differences. <i>Cognitive and Behavioral Neurology</i> , 2019, 32, 225-235.	0.9	3
39	Cognitive impairment and cardiovascular disease related to alexithymia in a well-controlled HIV-infected population. <i>Infezioni in Medicina</i> , 2019, 27, 274-282.	1.1	3
40	Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey. <i>Infezioni in Medicina</i> , 2021, 29, 54-64.	1.1	3
41	Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, e11-e14.	2.1	2
42	HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV. <i>Psychological Reports</i> , 2023, 126, 1181-1200.	1.7	2
43	The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition. <i>Journal of NeuroVirology</i> , 2020, 26, 899-907.	2.1	1
44	The facial emotion recognition deficit in Parkinson's disease: Implications of a visual scanning strategy. <i>Neuropsychology</i> , 2022, 36, 279-287.	1.3	1
45	Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV. <i>Journal of NeuroVirology</i> , 2022, 28, 422-429.	2.1	1
46	Writing errors in primary progressive aphasia. <i>Applied Neuropsychology Adult</i> , 2020, , 1-8.	1.2	0